Industry / Germany
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Boehringer Ingelheim Finally Increases Presence
July 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
India is one the leading emerging markets for pharmaceutical companies. Sales of medicines are experiencing double digit growth each year, low labour costs makes it a premier manufacturing hub, and the vast treatment-naïve population makes it an attractive location for clinical trials. Accordingly, it would be safe to presuppose that every multinational drugmaker has a sizeable presence on the sub-continent? The answer is a surprising no and German firm Boehringer Ingelheim is one of them. BMI takes a look at the tactics being employed by the Rhineland-Palatinate company to penetrate the Indian